COVID-19 Update: Many people are being asked to stay home to slow the spread of COVID-19... Many people are being asked to stay home to slow the spread of COVID-19. INBRIJA® (levodopa inhalation powder) continues to be delivered directly to patients' residences, so you can still receive your medication even if you are homebound for a prolonged period of time... See more >
Patient Information

Tools and Resources

INBRIJA® Tools & Resources

The INBRIJA Resource Center offers tools and resources to help you. Use these as often as you like. The more you know about OFF periods and your medication, the more your doctor can help you manage your OFF periods.

Choose, Engage, and Learn: An Educational Program Designed With You In Mind

Join us for FREE educational programs presented by leading Parkinson's experts. These programs are open to People with Parkinson's and their Care Partners.

Helpful resources for managing your Parkinson’s OFF periods

Real INBRIJA Story

Watch a video about Bob, a person with Parkinson’s who uses INBRIJA when his symptoms return.

Speaking Up About OFF Periods

This doctor discussion guide will help you prepare to make the most of your next doctor visit.

INBRIJA Brochure

An overview of OFF periods and INBRIJA as a treatment option.

Sign-Up

Provide your mailing address to get a FREE print copy of the INBRIJA Brochure, the Doctor Discussion Guide, and more helpful information.

INBRIJA Demonstration Video

Walking you through the steps for using INBRIJA.

Helpful Hints for Using INBRIJA

Helpful hints to make your experience as smooth as possible.

Just Ask Peter℠

Watch Peter provide answers to
questions you may have.

Common Questions

Explore a list of frequently asked questions.



Find a Parkinson's community event near you

American Parkinson
Disease Association

Caregiver Action Network

Davis Phinney Foundation
for Parkinson's

The Michael J. Fox Foundation

Parkinson's Foundation

Parkinson & Movement
Disorder Alliance

Have questions?

Contact us at 1‑833‑INBRIJA

Previous Page
For people on INBRIJA
Next Page
Common questions

INBRIJA® Indication

Treats OFF periods in adults taking carbidopa/levodopa (CD/LD). INBRIJA doesn’t replace CD/LD.

Important Safety Information

Don’t use if you have taken a nonselective monoamine oxidase inhibitor (eg, phenelzine, tranylcypromine) within the last 2 weeks.

See More

Indication

INBRIJA is a prescription medicine used when needed for OFF episodes in adults with Parkinson’s treated with regular carbidopa/levodopa medicine. INBRIJA does not replace regular carbidopa/levodopa medicine.

Important Safety Information

Do not use INBRIJA if you take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last 2 weeks.

Before using INBRIJA, tell your healthcare provider about your medical conditions, including:

  • asthma, chronic obstructive pulmonary disease (COPD), or any chronic lung disease
  • daytime sleepiness, sleep disorders, sleepiness/drowsiness without warning, or use of medicine that increases sleepiness, including antidepressants or antipsychotics
  • dizziness, nausea, sweating, or fainting when standing up
  • abnormal movement (dyskinesia)
  • mental health problems such as hallucinations or psychosis
  • uncontrollable urges like gambling, sexual urges, spending money, or binge eating
  • glaucoma
  • pregnancy or plans to become pregnant. It is unknown if INBRIJA will harm an unborn baby.
  • breastfeeding or plans to breastfeed. Levodopa can pass into breastmilk and it is unknown if it can harm the baby.

Tell your healthcare provider if you take:

  • MAO-B inhibitors
  • dopamine (D2) antagonists (including phenothiazines, butyrophenones, risperidone, metoclopramide)
  • isoniazid
  • iron salts or multivitamins that contain iron salts

Do not drive, operate machinery, or do other activities until you know how INBRIJA affects you. Sleepiness and falling asleep suddenly can happen as late as a year after treatment is started.

Tell your healthcare provider if you experience the following side effects:

  • falling asleep during normal daily activities with or without warning. If you become drowsy, do not drive or do activities where you need to be alert. Chances of falling asleep during normal activities increases if you take medicine that cause sleepiness.
  • withdrawal-emergent hyperpyrexia and confusion (fever, stiff muscles, or changes in breathing and heartbeat) if you suddenly stop using INBRIJA or carbidopa/levodopa, or suddenly lower your dose of carbidopa/levodopa.
  • low blood pressure when standing up (that may be with dizziness, fainting, nausea, and sweating). Get up slowly after sitting/lying down.
  • hallucinations and other psychosis – INBRIJA may cause or worsen seeing/hearing/believing things that are not real; confusion, disorientation, or disorganized thinking; trouble sleeping; dreaming a lot; being overly suspicious or feeling people want to harm you; acting aggressive; and feeling agitated/restless.
  • unusual uncontrollable urges such as gambling, binge eating, shopping, and sexual urges has occurred in some people using medicine like INBRIJA.
  • uncontrolled, sudden body movements (dyskinesia) may be caused or worsened by INBRIJA. INBRIJA may need to be stopped or other Parkinson’s medicines may need to be changed.
  • bronchospasm – people with asthma, COPD, or other lung diseases may wheeze or have difficulty breathing after inhaling INBRIJA. If this occurs, stop taking INBRIJA and seek immediate medical attention.
  • increased eye pressure in patients with glaucoma. Your healthcare provider should monitor this.
  • changes in certain lab values including liver tests

The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.

Do not orally inhale more than 1 dose (2 capsules) for any OFF period. Do not take more than 5 doses (10 capsules) in a day.

Please see the Patient Information Leaflet.